The SARS-CoV-2 spike (S) protein is the target of vaccine design efforts to end the COVID-19 pandemic. Despite a low mutation rate, isolates with the D614G substitution in the S protein appeared early during the pandemic, and are now the dominant form worldwide. Here, we analyze the D614G mutation in the context of a soluble S ectodomain construct.
Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Source:
Recombinant SARS-Cov-2 Spike protein(BA.2.86) is expressed in HEK293 cell with C-T4 foldon domain&His. It contains the amino acid sequence of 16-1213/1273
Expression System:
HEK293
Purity:
> 90% as determined by SDS- PAGE
* VAT and and shipping costs not included. Errors and price changes excepted
